Login / Signup

Deoxyshikonin reversibly inhibits cytochrome P450 2B6.

Jong Oh KimSu Min ChoiRiya ShreathaGil-Saeng JeongTae Cheon JeongSang-Kyu Lee
Published in: Biopharmaceutics & drug disposition (2020)
Deoxyshikonin, a natural shikonin derivative, is the major component of Lithospermum erythrorhizon and exhibits various pharmacological effects such as lymphangiogenetic, antibacterial, wound healing, and anticancer effects. To investigate the herb-drug interaction potential associated with deoxyshikonin, the inhibitory effects of deoxyshikonin on eight major cytochrome P450 (CYP) enzymes were examined using cocktail substrate-incubated human liver microsomes. Deoxyshikonin strongly inhibited CYP2B6-catalyzed bupropion hydroxylation, with a Ki value of 3.5 μM, and the inhibition was confirmed using purified human CYP2B6. The inhibition was reversible because the inhibitory effect of deoxyshikonin was not dependent on the preincubation time. The results indicated that deoxyshikonin-induced drug-drug interaction should be considered when any herb containing deoxyshikonin is used for conventional medications.
Keyphrases
  • wound healing
  • emergency department
  • squamous cell carcinoma
  • radiation therapy
  • diabetic rats
  • neoadjuvant chemotherapy
  • climate change
  • induced pluripotent stem cells
  • room temperature